

CITATION REPORT

List of articles citing

Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension

DOI: 10.1164/rccm.201507-1398oc

American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1102-10.

Source: <https://exaly.com/paper-pdf/62663454/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
120	Screening and Early Detection of Pulmonary Arterial Hypertension in Connective Tissue Diseases. It Is Time to Institute It!. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 192, 1032-3	10.2	6
119	Vascular Remodelling and Mesenchymal Transition in Systemic Sclerosis. 2016 , 2016, 4636859		25
118	Beyond a single pathway: combination therapy in pulmonary arterial hypertension. 2016 , 25, 408-417		38
117	Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. 2016 , 102 Suppl 2, ii67-85		43
116	Exhaled nitric oxide in pulmonary arterial hypertension associated with systemic sclerosis. 2016 , 6, 545-550		7
115	Pulmonary veno-occlusive disease. 2016 , 47, 1518-34		134
114	Initial dual oral combination therapy in pulmonary arterial hypertension. 2016 , 47, 1727-36		85
113	A Diagnosis at Hand: Pulmonary Arterial Hypertension. 2016 , 129, 812-5		
112	Independence Day: Separating Right Ventricular Function From Pulmonary Arterial Hypertension in Systemic Sclerosis. 2016 , 133, 2345-7		5
111	Pulmonary hypertension. 2016 , 25, 4-11		27
110	Mixed connective tissue disease. 2016 , 30, 95-111		60
109	Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. 2016 , 4, 894-901		37
108	[Targeted therapy of pulmonary arterial hypertension: Recommendations of the Cologne Consensus Conference 2016]. 2016 , 141, S33-S41		12
107	Connective tissue disease-related pulmonary arterial hypertension. 2016 , 30, 22-38		26
106	Update in Pulmonary Vascular Disease 2015. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 193, 1337-44	10.2	2
105	Ambrisentan in pulmonary arterial hypertension: a guide to its use in the EU. 2016 , 32, 50-59		
104	The quest for biomarker discovery in pulmonary arterial hypertension: the right takes lessons from the left. 2016 , 102, 335-6		1

103	Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). 2016 , 18, 10		28
102	Combination or monotherapy for pulmonary arterial hypertension?. 2016 , 4, 247-9		2
101	Non-Sexual Implications of Phosphodiesterase Type 5 Inhibitors. 2017 , 5, 170-199		11
100	Mechanism and prognostic role of qR in V in patients with pulmonary arterial hypertension. 2017 , 50, 476-483		13
99	Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. 2017 , 76, 1219-1227		96
98	Ambrisentan: a review of its use in pulmonary arterial hypertension. 2017 , 11, 233-244		12
97	Evaluation and management approaches for scleroderma lung disease. 2017 , 11, 327-340		13
96	Epidemiology and treatment of pulmonary arterial hypertension. 2017 , 14, 603-614		182
95	The effectiveness of upfront pulmonary vasodilators combination therapy in addition to corticosteroids for pulmonary arterial hypertension associated with systemic lupus erythematosus: two successful cases utilising both corticosteroids and an upfront combination of vasodilators. 2017 , 1, 73-78		1
94	Magnetic Resonance Imaging in the Prognostic Evaluation of Patients with Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 228-239	10.2	79
93	Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension. 2017 , 14, 682-689		10
92	Pulmonary Hypertension Complicating Connective Tissue Disease. 2017 , 38, 619-635		4
91	New insights into the recognition, classification and management of systemic sclerosis-associated pulmonary hypertension. 2017 , 29, 561-567		3
90	Magnetic Resonance Imaging in Pulmonary Arterial Hypertension. Panacea or Pixelation?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 129-131	10.2	0
89	Upfront combination therapy reduces right ventricular volumes in pulmonary arterial hypertension. 2017 , 49,		34
88	Measuring the effects of treatment in patients with PAH: should we image the right ventricle?. 2017 , 49,		0
87	The evolving landscape of combination therapy for pulmonary arterial hypertension. 2017 , 11, 91-95		1
86	Complex Pathophysiology of Pulmonary Hypertension Associated with Systemic Sclerosis: Potential Unfavorable Effects of Vasodilators. 2017 , 2, 92-99		5

85	Translating Autoimmune Pathogenesis into Targeted Therapies for Systemic Sclerosis. 2017 ,	
84	Recent advances in managing systemic sclerosis. 2017 , 6, 88	3
83	The success of pulmonary hypertension treatment: improved cardiac function by reducing the arterial load. 2018 , 8, 2045894018761632	
82	Can cardiovascular magnetic resonance prompt early cardiovascular/rheumatic treatment in autoimmune rheumatic diseases? Current practice and future perspectives. 2018 , 38, 949-958	15
81	An Update on Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: a Review of the Current Literature. 2018 , 20, 10	15
80	CCL21 as a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis. 2018 , 70, 1644-1653	18
79	The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study. 2018 , 8, 2045893217748307	21
78	Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodYnamic long-term efficacy (ITALY study). 2018 , 19, 12-17	15
77	Validation of a risk assessment instrument for pulmonary arterial hypertension. 2018 , 39, 4182-4185	10
76	Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 388-391	10.2 24
75	Scleroderma with Fibrosing Interstitial Lung Disease: Where Do We Stand?. 2018 , 15, 1273-1275	4
74	Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?. 2018 , 14, 253-264	20
73	Pulmonale Hypertonie und rheumatische Erkrankungen. 2018 , 15, 396-403	
72	Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. 2018 , 272S, 37-45	33
71	Ambrisentan + tadalafil in WHO functional class II/III pulmonary arterial hypertension: a guide to its use in the EU. 2018 , 34, 289-299	
70	Aggressive combination therapy for treatment of systemic sclerosis-associated pulmonary hypertension.. 2018 , 3, 30-38	2
69	Reply to Voelkel and Newman: The Light at the End of the Long Pulmonary Hypertension Tunnel Brightens. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 820-821	10.2
68	Right Ventricle Remodeling and Function in Scleroderma Patients. 2018 , 2018, 4528148	4

67	Pulmonary Circulation on the Crossroads Between the Left and Right Heart in Systemic Sclerosis: A Clinical Challenge for Cardiologists and Rheumatologists. 2018 , 14, 271-281		8
66	Major lung complications of systemic sclerosis. 2018 , 14, 511-527		43
65	Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, e15-e43	10.2	105
64	Effect of Combination Therapy of Endothelin Receptor Antagonist and Phosphodiesterase-5 Inhibitor on Clinical Outcome and Pulmonary Haemodynamics in Patients with Pulmonary Arterial Hypertension: A Meta-Analysis. 2019 , 39, 1031-1044		4
63	Advances in Management of Pulmonary Hypertension Associated with Systemic Sclerosis. 2019 ,		1
62	Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment. 2019 , 244, 120-131		16
61	Right ventricular systolic to diastolic duration ratio: A novel predictor of outcome in adult idiopathic pulmonary arterial hypertension. 2019 , 293, 218-222		7
60	Therapeutic Challenges And Advances In The Management Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension (SSc-PAH). 2019 , 15, 1427-1442		6
59	Pulmonary Arterial Hypertension In Systemic Sclerosis: Challenges In Diagnosis, Screening And Treatment. 2019 , 11, 323-333		8
58	Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension. 2019 , 9, 2045894019826944		8
57	Casting a Spotlight on the Right Ventricle in Systemic Sclerosis. 2019 , 71, 662-663		2
56	Risk stratification and medical therapy of pulmonary arterial hypertension. 2019 , 53,		316
55	Identification of Cardiac Magnetic Resonance Imaging Thresholds for Risk Stratification in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, 458-468	10.2	37
54	The importance of right ventricular evaluation in risk assessment and therapeutic strategies: Raising the bar in pulmonary arterial hypertension. 2020 , 301, 183-189		22
53	Pharmacologic therapy for pulmonary artery hypertension. 2020 , 35, 643-656		1
52	Evaluation and management of pulmonary arterial hypertension. 2020 , 171, 106099		9
51	Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan-tadalafil in pulmonary arterial hypertension. 2020 , 39, 1389-1397		3
50	Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension. 2020 , 10, 2045894020957234		3

49	An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis. 2020 , 21, 2041-2056		4
48	Cardiac Magnetic Resonance in Pulmonary Hypertension-an Update. 2020 , 13, 30		3
47	Diagnostic and prognostic markers and treatment of connective tissue disease-associated pulmonary arterial hypertension: current recommendations and recent advances. 2020 , 16, 993-1004		4
46	Effect of ambrisentan on echocardiographic and Doppler measures from patients in China with pulmonary arterial hypertension. 2020 , 18, 643-649		0
45	Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies. 2020 , 10, 2045894020963836		6
44	Reduced RVSWI Is Associated With Increased Mortality in Connective Tissue Disease Associated Pulmonary Arterial Hypertension. <i>Frontiers in Cardiovascular Medicine</i> , 2020 , 7, 77	5-4	1
43	Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort. <i>Arthritis Research and Therapy</i> , 2020 , 22, 56	5-7	6
42	Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment. 2020 , 21,		8
41	Management of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis. 2020 , 13, 15-29		13
40	Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis. 2020 , 79, 626-634		11
39	Characteristics of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Anticentriole Autoantibodies. 2020 , 61, 413-418		4
38	Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 484-492	10.2	12
37	The effects of oral treatment for systemic sclerosis related pulmonary arterial hypertension: A systematic review and meta-analysis. 2021 , 31, 151-161		2
36	Performance Under Pressure: The Relevance of Pulmonary Vascular Response to Exercise Challenge in Scleroderma. 2021 , 159, 481-483		1
35	Recent advances in the management of pulmonary arterial hypertension: lessons from the upfront combination of ambrisentan and tadalafil. 2021 , 15, 493-504		2
34	Significance of autoimmune disease in severe pulmonary hypertension complicating extensive pulmonary fibrosis: a prospective cohort study. 2021 , 11, 20458940211011329		3
33	Cardiovascular magnetic resonance predicts all-cause mortality in pulmonary hypertension associated with heart failure with preserved ejection fraction. 2021 , 37, 3019-3025		0
32	Systemic Sclerosis-Associated Pulmonary Hypertension: Spectrum and Impact. 2021 , 11,		6

31	Echocardiography in Pulmonary Arterial Hypertension: Is It Time to Reconsider Its Prognostic Utility?. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
30	A randomized, double-blind, placebo-controlled study to evaluate sildenafil, ambrisentan combination therapy in pulmonary hypertension, particularly of Eisenmenger syndrome. 2021 , 73, 633-636		1
29	Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis. 2021 , 28, 1007-1019		2
28	Translational Advances in the Field of Pulmonary Hypertension. Focusing on Developmental Origins and Disease Inception for the Prevention of Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 292-301	10.2	32
27	Emerging role of cardiovascular magnetic resonance imaging in the management of pulmonary hypertension. 2020 , 29,		10
26	The 6th World Symposium on Pulmonary Hypertension: what's old is new. 2019 , 8,		49
25	Circulating Angiotensin II Is Not a Biomarker of Disease Severity or Prognosis in Pulmonary Hypertension. 2016 , 11, e0165982		5
24	New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension. 2019 , 26, 2844-2864		11
23	Current status of pulmonary arterial hypertension in Korea. 2019 , 34, 696-707		6
22	Systemic Sclerosis and Other Connective Tissue Diseases. 2017 , 16, 55-60		
21	Gaps and Controversies of New Treatment Recommendations in Recent Pulmonary Hypertension Guidelines: What We Know and What We Don't. 2017 , 16, 20-25		
20	Author Response: Pulmonary Vasodilators in Sarcoidosis-associated Pulmonary Hypertension. <i>Clinical Medicine and Research</i> , 2020 , 18, 55-57	1.4	
19	Pulmonary Hypertension Associated with Connective Tissue Disease. <i>Cardiology Clinics</i> , 2022 , 40, 29-43	2.5	1
18	The REPAIR Study: Effects of Macitentan on RV Structure and Function in Pulmonary Arterial Hypertension. <i>JACC: Cardiovascular Imaging</i> , 2021 ,	8.4	4
17	Validity of the ESC Risk Assessment in Idiopathic Pulmonary Arterial Hypertension in China. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 745578	5.4	1
16	Pulmonary Hypertension in Children across Africa: The Silent Threat. <i>International Journal of Pediatrics (United Kingdom)</i> , 2021 , 2021, 9998070	2.1	
15	Cytokine signatures differentiate systemic sclerosis patients at high versus low risk for pulmonary arterial hypertension.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 39	5.7	1
14	Causes and outcomes of ICU hospitalisations in patients with pulmonary arterial hypertension.. <i>ERJ Open Research</i> , 2022 , 8,	3.5	0

13	Systemic Scleroderma-Definition, Clinical Picture and Laboratory Diagnostics.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	0
12	The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future.. <i>Pharmacology & Therapeutics</i> , 2022 , 108192	13.9	1
11	Outcome of mean pulmonary arterial pressure-based intensive treatment for patients with pulmonary arterial hypertension.. <i>Journal of Cardiology</i> , 2022 ,	3	1
10	Defining minimal detectable difference in echocardiographic measures of right ventricular function in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2022 , 24,	5.7	0
9	Combinatorial approaches for novel cardiovascular drug discovery: a review of the literature. <i>Expert Opinion on Drug Discovery</i> , 1-19	6.2	0
8	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. 2200879		18
7	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.		58
6	Haemodynamic effects of initial combination therapy in pulmonary arterial hypertension: a systematic review and meta-analysis. 00313-2022		0
5	Pulmonary Hypertension in Scleroderma Evaluation and Management. 2022 , 101468		0
4	Improved Survival for Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension: The Johns Hopkins Registry.		2
3	Pulmonary Hypertension Association& 2022 International Conference Scientific Sessions Overview.		0
2	Interstitial Lung Disease. 2023 , 49, 279-293		0
1	Pulmonary Hypertension. 2023 , 49, 345-357		0